🧠 Neuroprotection Peptides

A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.

Dose: 200–600 mcg intranasal, morning

A nonapeptide originally isolated from rabbit blood after EEG-defined slow-wave sleep induction. Inconsistent human evidence for sleep but explored for stress and analgesia.

Dose: 100–300 mcg before bed (subcutaneous)

An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.

Dose: Trial range: 1–4 mg subcutaneous daily

A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.

Dose: Trial range: 5–30 mL daily (intravenous infusion)

An angiotensin IV-derived hexapeptide that mimics hepatocyte growth factor (HGF)/c-Met signaling and produced rapid synaptogenesis in animal models. No human trials.

Dose: 8–45 mg orally daily (research-only)

A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).

Dose: 50 mcg intranasal, 4 times daily (CIRS protocols)

A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.

Dose: Research range: 0.5–1 mg subcutaneous (rare clinical use)